Atea Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 75
- Market Cap
- $324.1M
- Website
- http://www.ateapharma.com
Effect of Cyclosporine on the Pharmacokinetics (PK) of AT-527 (R07496998)
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2021-08-02
- Lead Sponsor
- Atea Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04849299
- Locations
- 🇨🇦
Atea Study Site, Montreal, Quebec, Canada
Effect of Carbamazepine on the Pharmacokinetics (PK) of AT-527
Phase 1
Completed
- Conditions
- Healthy Volunteer Study
- First Posted Date
- 2021-03-05
- Last Posted Date
- 2021-07-29
- Lead Sponsor
- Atea Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04784000
- Locations
- 🇨🇦
Atea Study Site, Montreal, Quebec, Canada
Study of AT-752 in Healthy Subjects
- First Posted Date
- 2021-01-25
- Last Posted Date
- 2022-10-17
- Lead Sponsor
- Atea Pharmaceuticals, Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT04722627
- Locations
- 🇦🇺
Atea Study Site, Melbourne, Victoria, Australia
Study of AT-527 in Healthy Subjects (R07496998)
Phase 1
Completed
- Conditions
- Healthy Volunteer Study
- Interventions
- First Posted Date
- 2021-01-15
- Last Posted Date
- 2022-02-25
- Lead Sponsor
- Atea Pharmaceuticals, Inc.
- Target Recruit Count
- 81
- Registration Number
- NCT04711187
- Locations
- 🇨🇦
Atea Study Site, Montréal, Quebec, Canada
Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) in a Hospital Setting
- First Posted Date
- 2020-05-20
- Last Posted Date
- 2023-03-09
- Lead Sponsor
- Atea Pharmaceuticals, Inc.
- Target Recruit Count
- 83
- Registration Number
- NCT04396106
- Locations
- 🇺🇦
Atea Study Site, Kyiv, Ukraine
Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects
Phase 1
Withdrawn
- Conditions
- HCV InfectionHepatitis CHepatitis C, ChronicChronic Hepatitis CHepatitis C Virus Infection
- Interventions
- First Posted Date
- 2020-03-16
- Last Posted Date
- 2022-06-08
- Lead Sponsor
- Atea Pharmaceuticals, Inc.
- Registration Number
- NCT04309734
- Locations
- 🇧🇪
Clinical Trial Site, Antwerp, Belgium
Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection
Phase 2
Completed
- Conditions
- Hepatitis CHepatitis C, ChronicChronic Hepatitis CHepatitis C Virus InfectionHCV Infection
- Interventions
- First Posted Date
- 2019-07-15
- Last Posted Date
- 2020-05-04
- Lead Sponsor
- Atea Pharmaceuticals, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT04019717
- Locations
- 🇲🇩
Clinical Trial Site, Chisinau, Moldova, Republic of
Study of AT-527 in Healthy and HCV-Infected Subjects
Phase 1
Completed
- Conditions
- Chronic Hepatitis CHepatitis CHepatitis C, Chronic
- Interventions
- Other: Placebo Comparator
- First Posted Date
- 2017-07-18
- Last Posted Date
- 2020-02-18
- Lead Sponsor
- Atea Pharmaceuticals, Inc.
- Target Recruit Count
- 88
- Registration Number
- NCT03219957
- Locations
- 🇲🇩
Clinical Trial Site, Chisinau, Moldova, Republic of
© Copyright 2025. All Rights Reserved by MedPath